Two oral diabetes medicines can be compared without pretending that all tablets have the same effect. PIONEER 3 directly compared oral semaglutide with sitagliptin in people whose diabetes was not adequately controlled with metformin, with or without a sulfonylurea. The trial helps answer a specific treatment-comparison question.
A direct comparator adds useful information
The randomized study enrolled 1,864 adults. Its primary assessment concerned HbA1c at week 26, with weight as a key secondary endpoint. Two semaglutide regimens produced greater reductions in both outcomes than sitagliptin, while the lowest study regimen did not establish noninferiority for HbA1c. See the primary PIONEER 3 report.
That distinction prevents a blanket statement that every semaglutide tablet exposure outperformed the comparator. The result depends on the studied regimen as well as the named ingredient.
Define which benefit matters
A comparison can favor one intervention for HbA1c and still leave other questions unresolved. The relevant decision may also involve tolerability, current medical conditions, treatment burden or the person’s existing plan.
Write the desired outcome before comparing products. “Better” becomes more informative when it means a particular glucose goal or another clearly stated priority, rather than a general ranking detached from clinical context.
Separate trial completion from treatment continuation
The paper reports both study completion and premature treatment discontinuation. Those are different measures: participants can remain under observation even if they stop the assigned medicine. A high trial-completion percentage should not be presented as though everyone stayed on treatment.
This distinction is useful when reading claims about how easy a medicine is to take. Ask which denominator is being used and whether the statement concerns follow-up attendance, adherence or tolerability.
Use direct evidence without overstating it
PIONEER 3 informs the comparison in its specified diabetes population and background therapy. It is not an obesity-treatment trial in adults without diabetes, nor does it establish the performance of compounded drops or an unrelated tablet.
Current labeling also matters when choosing among actual products. The oral semaglutide landscape has changed since this 2019 trial, so the historical intervention should not be mistaken for every formulation now bearing a semaglutide brand name.
Bring the existing prescription record and treatment goal to the clinician. Ask how this direct comparison is relevant, what it leaves unanswered and what alternatives address the same goal. The trial can improve the discussion without supplying a self-directed switch or a universal winner.
Sources and reading scope
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.